Question from the forum “Behind the wheel” – we answer them from time to time:
Why does the Ministry of the Interior consider color coding medicines that could impair driving after use? The idea has merit. Not everyone has the patience to read the long medical fine print that accompanies many drugs. Some simply do not know that certain medicines, such as antihistamines, can cause drowsiness. Others know but forget. A vivid warning on the package makes it easier to remember and act on.
By law, motorists are prohibited from getting behind the wheel while intoxicated, regardless of the reason. Taking medications that affect driving does not excuse the driver from responsibility. This can lead to disqualification if detected or suspected.
In practice, traffic police are unlikely to issue fines specifically for “drowsiness.” Yet some drivers may choose not to travel when they are under the influence of a drug like claritin or zodak during allergy season. The idea is to reduce the risk by making the impairment more obvious before the trip begins.
Alexander Bykov, head of the Moscow State Traffic Inspectorate, said that the introduction of special labels on packaging for drugs that influence driving and a list of such medicines has support from the Russian Ministry of Internal Affairs. He is the author of the proposal. For medicines with anesthetic properties, it makes sense to apply the highest level of prominence on the label.
The topic invites further questions about how safety labels could impact daily driving, medical choices, and overall road conduct. Readers with inquiries are encouraged to consider consultative resources that focus on safe driving practices while taking medications.
- Information about which drugs are incompatible with driving is available in educational materials within the public health system.
- Content discussing driving and medication safety is available in official channels for broad accessibility.